エストニア - エストニア語 - Ravimiamet

krka, d.d., novo mesto - metoprolool - toimeainet prolongeeritult vabastav tablett - 50mg 84tk; 50mg 56tk; 50mg 14tk; 50mg 30tk; 50mg 60tk; 50mg 98tk; 50mg 250tk; 50mg 50tk

エストニア - エストニア語 - Ravimiamet

krka, d.d., novo mesto - metoprolool - toimeainet prolongeeritult vabastav tablett - 200mg 84tk; 200mg 30tk; 200mg 14tk; 200mg 56tk; 200mg 50tk; 200mg 90tk; 200mg 28tk; 200mg 60tk; 200mg 100tk

エストニア - エストニア語 - Ravimiamet

krka, d.d., novo mesto - metoprolool - toimeainet prolongeeritult vabastav tablett - 25mg 90tk; 25mg 60tk; 25mg 100tk; 25mg 30tk; 25mg 10tk; 25mg 14tk; 25mg 50tk; 25mg 250tk; 25mg 28tk; 25mg 98tk

エストニア - エストニア語 - Ravimiamet

krka, d.d., novo mesto - metoprolool - toimeainet prolongeeritult vabastav tablett - 100mg 10tk; 100mg 30tk; 100mg 100tk; 100mg 50tk; 100mg 14tk; 100mg 56tk; 100mg 84tk; 100mg 60tk; 100mg 28tk

エストニア - エストニア語 - Ravimiamet

orifarm generics a/s - digoksiin - tablett - 62,5mcg 100tk; 62,5mcg 60tk

エストニア - エストニア語 - Ravimiamet

orifarm healthcare a/s - digoksiin - tablett - 0,25mg 60tk; 0,25mg 50tk

欧州連合 - エストニア語 - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

欧州連合 - エストニア語 - EMA (European Medicines Agency)

photonamic gmbh & co. kg - 5-aminolevuliinhappe vesinikkloriid - glioma - antineoplastilised ained - gliolan on näidustatud täiskasvanud patsientidel pahaloomulise kude visualiseerimiseks pahaloomulise glioomi operatsioonil (maailma terviseorganisatsiooni iii ja iv klass).

欧州連合 - エストニア語 - EMA (European Medicines Agency)

sanofi b.v. - türeotropiin alfa - kilpnäärme kasvajad - anterior hüpofüüsi lobe hormoonid ja nende analoogid, hüpofüüsi ja hüpotaalamuse hormoonid ja nende analoogid - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

欧州連合 - エストニア語 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) sarnane tüvi (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaktsiinid - aktiivne immuniseerimine gripiviiruse h5n1 alatüübi vastu. see näidustus põhineb immunogenicity andmeid tervisliku teemasid, alates vanusest 18 aastat aastast pärast manustamist kaks annust vaktsiini, mis on valmistatud alatüübi h5n1 tüve. prepandrix tuleks kasutada vastavalt euroopa liidu arendus.